within Pharmacolibrary.Drugs.ATC.C;

model C02KB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 160 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00038333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Metirosine (alpha-methyltyrosine) is a competitive inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis. It is used primarily to manage symptoms of pheochromocytoma, a catecholamine-secreting tumor, especially preoperatively or in patients where surgery is contraindicated. Its use today is rare and limited to specific indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates based on available secondary literature and drug labeling for healthy adult individuals; no detailed compartmental modeling PK study found.</p><h4>References</h4><ol><li><p>Nobusawa, A, et al., &amp; Oyama, T (2013). Diagnostic usefulness of ¹⁸F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma. <i>European journal of nuclear medicine and molecular imaging</i> 40(11) 1692–1700. DOI:<a href=&quot;https://doi.org/10.1007/s00259-013-2477-9&quot;>10.1007/s00259-013-2477-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23801167/&quot;>https://pubmed.ncbi.nlm.nih.gov/23801167</a></p></li><li><p>Valoti, M, et al., &amp; Sgaragli, GP (1992). Oxidative ring-coupling of tyrosine and its derivatives by purified rat intestinal peroxidase. <i>Biochemical pharmacology</i> 43(5) 945–951. DOI:<a href=&quot;https://doi.org/10.1016/0006-2952(92)90597-c&quot;>10.1016/0006-2952(92)90597-c</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1554392/&quot;>https://pubmed.ncbi.nlm.nih.gov/1554392</a></p></li><li><p>Galinelli, NC, et al., &amp; Bailey, SR (2025). Physiological and metabolic effects of short-term dopamine reduction in healthy horses using a tyrosine hydroxylase inhibitor (alpha-methyl-para-tyrosine). <i>Domestic animal endocrinology</i> 90 106891–None. DOI:<a href=&quot;https://doi.org/10.1016/j.domaniend.2024.106891&quot;>10.1016/j.domaniend.2024.106891</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39388740/&quot;>https://pubmed.ncbi.nlm.nih.gov/39388740</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C02KB01;
